Taylor Morrison Home
TMHC
Meritage Homes
MTH
D.R. Horton
DHI
Lennar Corp
LEN
Toll Brothers
TOL
US Stock MarketDetailed Quotes
TGTX TG Therapeutics
- 29.210
- +0.190+0.65%
Close Feb 25 16:00 ET
4.55BMarket Cap-292.10P/E (TTM)
29.735High28.390Low2.09MVolume28.890Open29.020Pre Close60.59MTurnover1.44%Turnover Ratio324.56P/E (Static)155.67MShares36.84052wk High23.67P/B4.23BFloat Cap12.93052wk Low--Dividend TTM144.91MShs Float149414.006Historical High--Div YieldTTM4.64%Amplitude0.956Historical Low29.044Avg Price1Lot Size
TG Therapeutics News
Institutional Investors in TG Therapeutics, Inc. (NASDAQ:TGTX) See US$243m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
TG Therapeutics Announces Presentation Schedule for BRIUMVI Data at ACTRIMS 2025 Conference
Express News | TG Therapeutics Announces Schedule of Data Presentations for Briumvi® (Ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (Ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
TG Therapeutics, Inc. (NASDAQ:TGTX) Investors Are Less Pessimistic Than Expected
Express News | MaxCyte, Inc. MaxCyte, Inc. - Mxcr - Strategic Platform License With TG Therapeutics
MaxCyte Signs Strategic Platform License With TG Therapeutics to Advance Its Autoimmune Cell Therapeutics Programs
Bank of America Securities Sticks to Its Sell Rating for TG Therapeutics (TGTX)
TD Cowen Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $50
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy
Institutional Investors Have a Lot Riding on TG Therapeutics, Inc. (NASDAQ:TGTX) With 75% Ownership
8 Health Care Stocks Whale Activity In Today's Session
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?
Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts
TG Therapeutics Analyst Ratings
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $55
Strong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG Therapeutics
TG Therapeutics Reports Strong Revenue and Future Goals
TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.